Wikisage, the free encyclopedia of the second generation, is digital heritage

Brexanolone: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
*3α-hydroxy-5α-pregnan-20-one
*3α-hydroxy-5α-pregnan-20-one
*allopregnanolone
*allopregnanolone
On MArch 19th FDA approved
On March 19th FDA approved
''Zulresso'' i.v. for depression post partum <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm</ref> or <ref>https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share</ref>
''Zulresso'' i.v. for depression post partum <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm</ref> or <ref>https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share</ref>


<references/>
{{refs}}


{{Wikidata|Q28487680}}
{{Wikidata|Q28487680}}
[[Category:GABAA receptor positive allosteric modulators]]

Latest revision as of 01:19, 7 May 2019

Brexanolone allotetrahydroprogesterone

  • 3α-hydroxy-5α-pregnan-20-one
  • allopregnanolone

On March 19th FDA approved Zulresso i.v. for depression post partum [1] or [2]

References

References:

Q28487680 at Wikidata  Interwiki via Wikidata